Image

Diagnostic Yeld of Ultrathin Bronchoscopy in Peripheral Pulmonary Lesions

Recruiting
18 years of age
Both
Phase N/A

Powered by AI

Overview

The use of an ultrathin bronchoscope (UB) has recently been introduced in the diagnosis of peripheral lung lesions. The use of the UB can be supported by navigation systems such as fluoroscopy, ultrasound guidance, electromagnetic navigation, or other technologies, which have complementary potential. Further navigation techniques are still under study. The use of ultrathin instrumentation has already been shown to significantly reduce procedural times compared to traditional instrumentation.

The purpose of the study is to prospectively evaluate the institutional experience of different third-level hospital centers with the use of a UB (MP190F; Olympus Medical Systems, Tokyo, Japan) for sampling peripheral lung lesions by means of transbronchial needle aspiration (TBNA) or transbronchial biopsy (TBB), performed after fluoroscopic navigation and simultaneous radial probe-endobronchial ultrasound (RP-EBUS) assessment.

Design: multicentric, observational study.

Eligibility

Inclusion criteria:

  • Candidate for a diagnostic procedure for a new peripheral lung lesion or re-biopsy;
  • Tissue sampling of the peripheral lesion performed only with UB;
  • The patient's ability to understand the individual characteristics and consequences of the clinical study;
  • Males and females of any ethnicity;
  • Subjects who have given their informed consent to use their clinical data for research purposes.

Exclusion criteria:

  • Inability to give informed consent or understand its contents;
  • Unavailability of tomographic imaging;
  • Failure to use RP-EBUS or fluoroscopic guidance during the procedure;
  • Failure to use R.O.S.E. by the pulmonologist or pathologist during the procedure;
  • Tissue sampling on the same peripheral lesion using an instrument of a different caliber in replacement or in association;
  • Any other significant illness or disorder that, in the investigator's opinion, may put the patient at risk due to study participation.

Study details

Lung Cancer, Lung; Node, Lung Diseases, Lung TB, Lung Adenocarcinoma

NCT05526573

Azienda Sanitaria-Universitaria Integrata di Udine

17 February 2024

Step 1 Get in touch with the nearest study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.